Research Article

Snezana Mugosa*, Ivan Radosavljevic, Majda Sahman, Natasa Djordjevic, Zoran Todorovic

Risk factors for adverse drug reactions associated with clopidogrel therapy

https://doi.org/10.1515/med-2021-0371
received December 16, 2020; accepted September 13, 2021

Abstract: This study aimed to investigate the possible influence of genetic and non-genetic factors on the incidence of clopidogrel adverse drug reactions (ADRs) in cardiology patients, including the most important CYP2C19 alleles, namely *2 and *17, as well as compliance, dose, drug interactions, and clinical factors. A total of 102 clopidogrel-treated adult Caucasian patients hospitalized at the Cardiology Department of the Clinical Center of Montenegro were enrolled in the study. Data on clinical outcomes of interest were obtained by intensive monitoring ADRs during hospitalization and one year after hospital discharge. Genotyping for CYP2C19*2 and *17 was conducted using the real-time polymerase chain reaction method. ADRs were characterized using the Rawlins and Thompson classification and the World Health Organization criteria. Causality was assessed using the Naranjo probability scale. ADRs to clopidogrel were observed in 9 of 102 patients (8.8%). The observed frequencies of CYP2C19*2 and *17 were 13.2 and 25.5%, respectively. Our study, which is the first to report the frequency of CYP2C19 polymorphism in the Montenegrin population, as well as to link the pharmacovigilance of clopidogrel with CYP2C19 gene variability, shows that the incidence of ADRs of clopidogrel in cardiac patients is high and depends on CYP2C19 polymorphisms, comedication/drug interactions, and gastrointestinal comorbidity.

Keywords: clopidogrel, adverse drug reactions, pharmacogenetics

1 Introduction

Clopidogrel is still used as an antiplatelet drug in a large number of cardiac patients. The safety of antiplatelet drugs should be reevaluated since it might have a significant impact on clinical practice. Data on antiplatelet agents’ relative safety are very complex to interpret and vary depending on several factors.

A study by the Italian Pharmacovigilance Network in 2017 revealed that clopidogrel seemed to be the most dangerous antiplatelet drug in Italian patients between 2009 and 2016; the total number of suspected adverse drug reactions (ADRs) reported was the following: clopidogrel (3,298) > ticlopidine (1,169) > ticagrelor (471) > prasugrel (126). However, if the rate of ADRs per the number of patients treated was compared, the rank of safety risk was different: ticagrelor > prasugrel = clopidogrel > ticlopidine [1]. Common ADRs of clopidogrel in patients include bleeding at the puncture site, hematoma, epistaxis, bruising, and gastrointestinal disorders such as gastrointestinal hemorrhage, diarrhea, abdominal pain, and dyspepsia [2]. Bleeding is the most commonly reported ADR in clinical studies and during post-marketing surveillance. In the CAPRIE study, the total incidence of any bleeding was 9.3% [3]. A recently published meta-analysis by Italian authors showed that the benefit/risk ratio for clopidogrel is more favorable than for the significantly more expensive drugs such as prasugrel and ticagrelor in patients on oral anticoagulant therapy for atrial fibrillation after a recent percutaneous coronary intervention [4].
In this cohort, the risk of clinically significant bleeding was higher if they had received ticagrelor or prasugrel rather than clopidogrel, without any additional benefit in reducing the frequency of major adverse cardiovascular events (MACE).

The interindividual variability in response to clopidogrel could be due to genetic factors (single nucleotide polymorphism of genes encoding for CYPs and P-glycoproteins) and nongenetic issues, including compliance, dosing regimen, drug interactions, and comorbidities [5]. In various studies, which included healthy volunteers of Caucasian and Asian ethnicities, a significant relationship among CYP2C19 genotype, differences in the pharmacokinetics of clopidogrel and its active metabolite, and antiplatelet response to clopidogrel has been established [6–8]. CYP2C19 is the most important enzyme in the metabolism of clopidogrel, which is a pro-drug because it participates in both stages of drug biotransformation to the active metabolite [6]. The gene that encodes has more than 14 allelic forms [6]. The enzyme encoded by *1 isoform normally metabolizes the drug, while the enzyme encoded by *2 isoform slowly metabolizes the drug, thus there is no expected therapeutic effect of the drug in patients with such isoforms after taking clopidogrel in usual doses (since the conversion of clopidogrel to the active metabolite by metabolism via cytochrome P450 is required for the achievement of the therapeutic effect of the drug). The CYP2C19*2/*2 allelic variant showed a strong correlation with a weaker response to clopidogrel, especially in patients younger than 45 years of age, which is considered to be the main cause of poor response to the therapy [9]. Patients with the CYP2C19 *17 isoform metabolize the drug rapidly and therefore have an increased incidence of clopidogrel ADRs [10]. Individualized clopidogrel treatment could optimize its benefit–risk ratio by reducing the risk of MACE and minimizing ADRs, such as bleeding.

This study aimed to investigate the possible influence of genetic (CYP2C19 allelic variants *2 and *17) and nongenetic factors (noncompliance, dose, drug interactions, clinical factors) on the incidence of clopidogrel ADRs in cardiology patients.

2 Methods

2.1 Study population

A prospective study involved 102 clopidogrel-treated adult Caucasian patients hospitalized at the Cardiology Department of the Clinical Center of Montenegro, Podgorica, Montenegro. Around half of them (54 of 102) were on clopidogrel treatment before admission to the hospital, while others were prescribed clopidogrel at the time of discharge from the hospital. Patients younger than 20 years or older than 80 years, those who were on anticoagulant therapy, had hematological disorders (hemoglobin < 100 g/L, platelet count < 100 × 10^9 cells/L or > 600 × 10^9 cells/L), malignant or chronic inflammatory diseases, pregnant women, nursing mothers, people with dementia, and patients who were not willing to sign the informed consent form, were not included in the study.

2.2 Definition and classification of ADRs

Data on clinical outcomes of interest were obtained by intensive monitoring of ADRs: (a) inperson, during hospitalization, and (b) by telephone survey during one year after hospital discharge.

ADRs were defined and characterized according to the World Health Organization (WHO) and the Rawlinson and Thompson classification. The causality relationship between the drug and the effect was established by using Naranjo’s ADR probability scale. ADRs were classified by Meyboom et al. as type A (“drug actions”), type B (“patients reactions”), and type C (“statistical”), while their severity was assessed as per the WHO criteria [11–15].

The level of intervention was attributed using a four-level scale (Level 1 – no change in the treatment; Level 2 – dose adjustment or drug stop, no additional treatment required; Level 3 – dose adjustment or drug stop, additional treatment required; Level 4 – transfer to intensive care unit) [16]. Each ADR was also classified according to the system organ class, (according to MedDRA classification of ADRs), as recommended by the WHO [17].

2.3 Polymerase chain reaction (PCR) measurements

For CYP2C19 genotyping, DNA was extracted from whole blood samples using PureLink® genomic DNA kit (Invitrogen, Carlsbad, CA). The DNA concentration was measured by the fluorometer Qubit® (Invitrogen, Carlsbad, CA), using the Qubit™ dsDNA HS Assay Kit (Invitrogen, Carlsbad, CA), and ranged from 2.4 to 24 μg/mL. Isolation of DNA was performed at the Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Serbia. Based on available literature and
CYP2C19 allele nomenclature, for the study, two variants of CYP2C19, namely rs4244285 (19154G > A, CYP2C19*2) and rs12248560 (~806C > T, CYP2C19*17), were chosen to be included in the analysis as the most common genetic determinants of slow and rapid metabolizers, respectively [18,19]. Genotyping was conducted at the Department of Immunology, Public Health Institute, Kragujevac, using real-time PCR method and predesigned TaqMan® Genotyping Assays C____25986767_70 and C____469857_10 (Applied Biosystems, Foster City, CA) for CYP2C19*2 and *17, respectively. The PCRs were performed in 20 µl reaction volume on SaCycler-96 RUO (SACACE Biotechnologies, Como, Italy), and the conditions constituted of initial denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 sec and annealing at 60°C for 1 min.

2.4 Statistics

Statistical data analysis was performed using IBM SPSS Statistics 22 (SPSS Inc., Chicago, IL, USA). Descriptive statistical methods (arithmetic mean with standard deviation, and median with (interquartile) range) and methods for testing statistical hypotheses (t-test, Mann–Whitney test, chi-square test, and Fisher’s test of exact probability) were used for the analysis of primary data. Statistical hypotheses were tested at the level of statistical significance (alpha level) of 0.05.

The study was conducted in accordance with the Declaration of Helsinki [20], with the approval of the Ethics Committee of the Clinical Center of Montenegro and the written consent of each of the participants. Also, the study was conducted in accordance with the International Conference on Harmonisation Guideline for Good Clinical Practice [21].

3 Results

Baseline clinical characteristics and demographics of the study population are presented in Table 1.

During the hospitalization period and 12 months after discharge from the hospital, ADRs to clopidogrel were observed in 9 of 102 patients (8.8%).

The median number of drugs used by patients with and without ADRs was 8 (range: 4–16) and 6 (range: 4–10), respectively (p = 0.027). Concomitant use of other drugs that are also metabolized through CYP2C19 was a significant risk factor for developing ADRs to clopidogrel.

Table 1: Demographic and clinical characteristics of the cardiac disease patients involved in the study

| Patients characteristics | Total (N = 102) | Patients with ADRs (N = 9) | Patients without ADRs (N = 93) | p-value |
|--------------------------|----------------|---------------------------|-------------------------------|--------|
| Age, mean ± sd           | 59.3 ± 9.1     | 56.7 ± 7.1                | 59.6 ± 9.2                    | 0.363  |
| Sex, N (%)               |                |                           |                               |        |
| Males                    | 70 (68.6 %)    | 5 (55.6 %)                | 65 (69.9 %)                   | 0.456  |
| Females                  | 32 (31.4 %)    | 4 (44.4 %)                | 28 (30.1 %)                   |        |
| BMI, mean ± sd           | 28.0 ± 3.6     | 26.4 ± 3.6                | 28.1 ± 3.6                    | 0.161  |
| Smoking, N (%)           | 45 (44.1 %)    | 4 (44.4 %)                | 41 (44.1 %)                   | 1.000  |
| Co-morbidity type, N (%) | 34 (33.3 %)    | 5 (55.6 %)                | 29 (31.2 %)                   | 0.156  |
| – Endocrine system       | 8 (7.8 %)      | 0 (0.0 %)                 | 8 (8.6 %)                     | 1.000  |
| – Respiratory system     | 3 (2.9 %)      | 0 (0.0 %)                 | 3 (3.2 %)                     | 1.000  |
| – Gastrointestinal system| 19 (18.6 %)    | 5 (55.6 %)                | 14 (15.1 %)                   | 0.010  |
| – Central nervous system | 5 (4.9 %)      | 0 (0.0 %)                 | 5 (5.4 %)                     | 1.000  |
| – Urinary system         | 3 (2.9 %)      | 0 (0.0 %)                 | 3 (3.2 %)                     | 1.000  |
| Number of co-morbidities|                |                           |                               | 0.188  |
| 0, N (%)                 | 68 (66.7 %)    | 4 (44.4 %)                | 64 (68.8 %)                   |        |
| 1, N (%)                 | 30 (29.4 %)    | 5 (55.6 %)                | 25 (26.9 %)                   |        |
| 2, N (%)                 | 4 (3.9 %)      | 0 (0.0 %)                 | 4 (4.3 %)                     |        |
| Risk factors for coronary artery disease |  |  |  |  |
| Arterial hypertension, N (%) | 75 (73.5 %) | 7 (77.8 %) | 68 (73.1 %) | 1.000  |
| Diabetes mellitus, N (%)  | 31 (30.4 %)    | 1 (11.1 %)                | 30 (32.3 %)                   | 0.270  |
| Hypercholesterolemia, N (%) | 47 (46.1 %)   | 5 (55.6 %)                | 42 (45.2 %)                   | 0.729  |
| Heredity, N (%)           | 38 (37.3 %)    | 3 (33.3 %)                | 35 (37.6 %)                   | 1.000  |
| Obesity, N (%)            | 21 (20.6 %)    | 2 (22.2 %)                | 19 (20.4 %)                   | 1.000  |
| Number of risk factors for coronary artery disease, median (range) | 3 (0–6) | 3 (1–4) | 3 (0–6) | 0.942  |

Bold values indicate statistically significant value.
These drugs include, for example, pantoprazole (28.4%), diazepam (13.7%), warfarin (1.9%), omeprazole (1.9%), and gliclazide (1.9%). The most commonly used pharmacotherapeutic groups of drugs in patients with comedication were antiplatelet drugs (18.7%), ACE inhibitors (11.9%), beta-blockers (9.5%), diuretics (9.3%), and statins (9.2%). The drugs that cause ADRs in patients most often belong to the following pharmacotherapeutic groups: beta-blockers (20.0%), ACE inhibitors (12.0%), organic nitrates (12.0%), anticoagulants (12.0%), and antiplatelet drugs (8.0%). The incidence of ADRs did not differ between males and females; patients with and without comorbidities, and those with and without risk factors for coronary artery disease had ADR. However, a higher percentage of patients with ADRs had gastrointestinal comorbidities than patients without ADRs (Table 1).

The distribution of CYP2C19 nucleotide changes, haplotypes, and genotypes is shown in Table 2.

Rapid metabolizers (carriers of CYP2C19*1/*17 genotype) had significantly more adverse clinical outcomes compared to slow (CYP2C19*1/*2), intermediate (CYP2C19*2/*17), or extensive (CYP2C19*1/*1) CYP2C19 metabolizers (p = 0.03; Figure 1).

Table 3 shows the characteristics of clopidogrel ADRs. *Certain ADRs were general disorders and administration site conditions (bleeding at puncture site), probable ADRs were hematological toxicities (hematuria, thrombocytopenia), and possible ADRs were respiratory, thoracic, and mediastinal disorders (epistaxis) and vascular disorders (hematoma).

All ADRs were expected, that is, described in the Summary of product characteristics for clopidogrel.

4 Discussion

The most important findings of our study show that the risk of clopidogrel ADRs is higher in rapid metabolizers, patients with gastrointestinal comorbidities, and those using comedications that are metabolized via CYP2C19. In addition, this is the first study reporting the distribution of the most important CYP2C19 polymorphisms, namely *2 and *17, in Montenegrin population.

The distribution of *1/*2 genotypes in our study fits published data for the Caucasians [22]. In contrast, we found more *1/*17 phenotype carriers than expected, but it could explain a slightly higher incidence of clopidogrel ADRs in our study than in the literature [23]. In the former Yugoslavian countries, excluding newly acquired data for Montenegro, CYP2C19 *2 and *17 allele frequencies range between 11 and 15%, and between 18 and 24%, respectively [24]. These values vary considerably across Europe, with no specific gradient relative to geographic region, as observed for CYP2D6 alleles. However, CYP2C19*2 alleles are somewhat more common in Northern and Western Europe and *17 alleles in Central Europe [24].

In addition to the high prevalence of *17 allele carriers, the relatively high incidence of clopidogrel ADRs in our study could also be explained by differences in methodology, definitions, and classifications of ADRs, algorithms for assessing the cause-and-effect relationship between drug and ADR, etc. [25]. We have included “possible” ADRs in the total frequency of ADRs, unlike, for example, Lazarou, who listed only “certain” and “probable” ADRs, so we possibly included some false-positive results [26].

Our sample mainly consists of elderly patients with different comorbidities. Age- and comorbidity-related changes in drug pharmacokinetics make patients more susceptible to ADRs, particularly to antithrombotic agents [27]. In general, age was identified as a major predictor of preventable harm from medicines [28,29]. However, in hepatogastroenterological patients, the overall risk of ADRs was not increased with advanced age, except for patients with biliary tract diseases. Therefore, more frequent clopidogrel ADRs in our patients with gastrointestinal comorbidities could be related to their age, but further analysis is needed.

The elderly also use more medications, which is also a significant risk factor for ADRs. In a study of 9,000 Italian patients, mostly over the age of 60 years, Carbonin et al. [30] showed that the incidence of ADRs increased from 1.2% in patients receiving only one drug to 10% in those receiving nine drugs, and to about 50% in patients receiving more than ten drugs. Grymonpre et al. [31]
examined the prevalence of ADRs in Canadian patients over the age of 50 years and showed that the incidence of ADRs increased from 5% in patients receiving two drugs to 20% and more in patients receiving five or more drugs. Some studies have shown that patients who receive 16 different medications during hospitalization have a 40% probability of experiencing some ADRs [32]. This could probably explain our finding of the significant difference in the incidence of clopidogrel ADRs in patients with comedinations. In particular, the interaction between clopidogrel and other drugs that are substrates for CYP2C19 may be an important risk predictor for ADRs, but it should be emphasized that not all such interactions are clinically important (e.g., clopidogrel + omeprazole vs clopidogrel + diazepam).

Numerous studies have shown that the female sex is a risk factor for ADRs, although there is no reliable explanation for this in the literature. Some authors believe that lower body weight and surface area and degree of glomerular filtration, as well as higher fat content, are the reason for the higher frequency of ADRs in the female population. However, sex-related differences in the safety profile of glycoprotein IIb/IIIa inhibitors could not be found in clinical trials, which is in agreement with our study [33].

As regarding the causality, we observed the highest prevalence of probable and possible ADRs, which does not differ significantly from the data obtained in similar studies, where more than 50% of reported ADRs were classified as “possible” and less than 10% as “certain” [16,34,35]. In contrast, Classen [36] describes 62% of ADRs as “certain” ADRs and 0.7% as “probable.” We found that the incidence of serious adverse reactions was 22.2% of the total number of reported ADRs. In a study conducted by the French Center for Pharmacovigilance, this percentage was 33%, and in a study by Somers et al. it reached 38% [37,38]. In some studies, this percentage is significantly lower, which is probably attributable to differences in methodology and the population covered by the study (e.g. 30).

Table 3: Characteristics of detected ADRs associated with clopidogrel therapy

| ADRs characteristics | n (%) |
|----------------------|-------|
| **Type**             |       |
| A                    | 9 (100%) |
| B                    | 0 (0%)   |
| C                    | 0 (0%)   |
| **Causality**        |       |
| Certain              | 1 (11.1%) |
| Probable             | 5 (55.5%) |
| Possible             | 3 (33.4%) |
| **Level of intervention** |       |
| Level 1 (no change in dose) | 7 (77.8%) |
| Level 2 (dose changed or the drug stopped) | 1 (11.1%) |
| Level 3 (drug stopped + additional therapy) | 1 (11.1%) |
| Level 4 (transfer to intensive care unit) | 0 (0.10%) |
| **Severity**         |       |
| Serious ADR          | 2 (22.2%) |
| Non serious ADR      | 7 (77.8%) |
| **Outcome**          |       |
| Death                | 0 (0%)   |
| Recovery with consequences | 0 (0%)   |
| Recovery without consequences | 9 (100%) |

*Causality was assessed using the Naranjo probability scale (WHO criteria).
In our study, ADRs were 100% of type A. Given the mechanism of occurrence of these types of ADRs, the prevalence we obtained was expected, although type B reactions may reach up to one-third of detected ADR [31]. Adverse reactions were most often manifested as general disorders and administration site conditions, hematological toxicities, respiratory, thoracic, and mediastinal disorders, and vascular disorders, which fits into the safety profile of clopidogrel [2].

The distribution of patients over the levels of intervention in our study is in agreement with published data. In a study conducted by Kaur et al., in 16.3% of cases, it was not necessary to change the dose of the drug; in 12% of cases, the dose was changed, while in 75.9%, additional treatment was required [39].

Many studies have shown that the percentage of preventable ADRs is high and ranges over 50% [39,40]. This can be achieved by careful assessment of the drug’s pharmacology, its safety profile, potential to interact with other drugs, pharmacological anamnesis, and its rational prescribing tailored to the individual patient’s needs [29]. Our study confirms the need for an individual approach in the use of clopidogrel, especially in those at higher risk of ADRs [41]. Last but not least, cost–utility analysis supports genotype-guided dual antiplatelet therapy with ASA and clopidogrel [42].

Finally, the main limitation of our research is the small sample size. Additional analysis on a larger sample is necessary to resolve some issues related to the influence of comorbidities and pharmacogenetics on the safety profile of clopidogrel (e.g., P–glycoprotein-coding gene polymorphism).

5 Conclusion

Our study showed that the incidence of ADRs of clopidogrel in cardiac patients is high, and depends on CYP2C19 gene polymorphisms, comedication/drug interactions, and gastrointestinal comorbidity. It is necessary to conduct continuous education of cardiologists in the safe use of drugs to improve their awareness of the ADRs of antiplatelet therapy and the related risk factors.

Our study, conducted according to the internationally accepted methodology, is the first to link the pharmacovigilance of clopidogrel and the pharmacogenetics of gene polymorphisms for CYP2C19 in the Montenegrin population. Further investigation in a large cohort is needed to clarify the still unresolved issues regarding the individualization of therapy and the safety profile of clopidogrel and other antiplatelet agents.

Acknowledgments: The study was financially supported by the Ministry of Science, Montenegro (grant No. 01-907).

Funding information: No funds.

Authors contributions: ZT designed the study and developed methodology. SM performed intensive monitoring ADRs and took the lead in writing the manuscript. ND performed PCR measurements. IR assisted in performing PCR measurements. MS carried out statistical analysis and assisted in writing the manuscript. All authors have read and agreed to the published version of the manuscript.

Conflict of interest: The authors declare no conflict of interest.

Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] Gozzo L, Navarria A, Benfatto G, Longo L, Mansueto S, Sottosanti L, et al. Safety of antiplatelet agents: analysis of ‘real-world’ data from the italian national pharmacovigilance network. Clin Drug Invest. 2017 Nov;37(11):1067–81. doi: 10.1007/s40261-017-0566-4.

[2] Plavix 75 mg film-coated tablets – Summary of Product Characteristics. EMA. https://www.ema.europa.eu/en/documents/product-information/plavix-epar-product-information_en.pdf. Accessed on August 20, 2021.

[3] Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Vasc Med. 1998;3(3):257–60. doi: 10.1177/1358836X9800300314.

[4] Casula M, Fortuni F, Ferlini M, Fabris F, Oltrona Visconti L, Leonardi S. Meta-analysis comparing potent oral P2Y12 inhibitors versus clopidogrel in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiovac Drugs. 2021;21(2):231–40. doi: 10.1007/s40256-020-00436-8.

[5] Mugoša S, Djordjević N, Bukumirić Z, Djukanović N, Cukić J, Radosavljević I, et al. PREDICT score and CYP2C19 polymorphism independently predict lack of efficacy of clopidogrel in cardiology patients. Clin Exp Pharmacol Physiol. 2016;43(3):379–81. doi: 10.1111/1440-1681.12531.

[6] Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest 2nd CS, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic...
response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5(12):2429–36. doi: 10.1111/j.1538-7836.2007.02775.x.

[7] Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119(19):2553–60. doi: 10.1161/CIRCULATIONAHA.109.851949.

[8] Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmaco kinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost. 2008;6(8):1439–41. doi: 10.1111/j.1538-7836.2008.03050.x.

[9] Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv. 2008 Dec;1(6):620–7. doi: 10.1016/j.jcin.2008.09.008.

[10] Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, et al. Genetic variation of CYP2C19 affects both pharmacoki netic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J. 2009 Jul;30(14):1744–52. doi: 10.1093/eurheartj/eur157.

[11] Nahler G. WHO-adverse reaction terminology (WHO-ART). Dictionary of pharmaceutical medicine. Vienna: Springer; 2009. doi: 10.1007/978-3-211-89836-9_1467. Accessed on December 5, 2020.

[12] Rawlins MD. Clinical pharmacology. Adverse reactions to drugs. Br Med J (Clin Res Ed). 1981 Mar 21;282(6268):974–6. doi: 10.1136/bmj.282.6268.974.

[13] Uppsala Monitoring Centre. http://www.who-umc.org/. Accessed on December 5, 2020.

[14] Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45. doi: 10.1038/clpt.1981.154.

[15] Meyboom RH, Lindquist M, Egberts AC. An ABC of drug-related problems. Drug Saf. 2000;22(6):415–23.

[16] Mugoša S, Bukumiršić S, Kovačević A, Bošković A, Protić D, Todorović Z. Adverse drug reactions in hospitalised cardiac patients: characteristics and risk factors. Vojnosanit Pregl. 2015;72(11):975–81. doi: 10.2298/VSP140710104M.

[17] December Medical Dictionary for Regulatory Activities – MedDRA. https://www.meddra.org/. Accessed on December 5, 2020.

[18] Dai ZL, Chen H, Wu XY. Relationship between cytochrome P650 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of cor onary artery disease treated with clopidogrel. Zhong Xi Yi Jie He Xue Bao. 2012;10(6):647–54. doi: 10.3736/jcim20120608.

[19] Mao L, Jian C, Changzhi L, Dan H, Sulhua H, Wenyi T, et al. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. Arch Cardiovasc Dis. 2013;106(10):517–27. doi: 10.1016/j.acvd.2013.06.055.

[20] World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4. doi: 10.1001/jama.2013.281053.

[21] ICH E6 (R2) Guideline for good clinical practice (last updated: 15/12/2016). https://www.ema.europa.eu/documents/scientific-guideline/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf. Accessed on December 5, 2020.

[22] Martis S, Peter I, Hulot JS, Komreich R, Desnick RJ, Scott SA. Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J. 2013;13(4):369–77. doi: 10.1038/tjp.2012.10.

[23] Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121(4):512–8. doi: 10.1161/CIRCULATIONAHA.109.885194.

[24] Petrović J, Pešić V, Lausckhe VM. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. Eur J Hum Genet. 2020;28(1):88–94. doi: 10.1038/s41431-019-0480-8.

[25] Brvar M, Fokter N, Bunc M, Mozina M. The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty. BMC Clin Pharmacol. 2009;9:8. doi: 10.1186/1472-6904-9-8.

[26] Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998 Apr 15;279(15):1200–5. doi: 10.1001/jama.279.15.1200.

[27] Monteiro C, Duarte AP, Alves G. Adverse drug reactions in elderly: a five-year review of spontaneous reports to the Portuguese pharmacovigilance system. Expert Opin Drug Saf. 2021 Jan;20(1):109–18. doi: 10.1080/14740338.2020.1849137.

[28] Nguyen TL, Leguelin-belche G, Kinowski JM, Roux-Marson C, Rougier M, Spence J, et al. Improving medication safety: development and impact of a multivariate model-based strategy to target high-risk patients. PLoS ONE. 2017;12(2):e0171995. doi: 10.1371/journal.pone.0171995.

[29] Ferner R, Aronson J. Susceptibility to adverse drug reactions. Br J Clin Pharmacol. 2019;85(10):2205–12. doi: 10.1111/bcp.14015.

[30] Carbonin P, Pahor M, Bernabei R, Sgadari A. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc. 1991;39(11):1093–9. doi: 10.1111/j.1532-5415.1991.tb02875.x.

[31] Grymonpre RE, Miltenko PA, Sitar DS, Aoki FY, Montgomery PR. Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc. 1988 Dec;36(12):1092–8. doi: 10.1111/j.1532-5415.1988.tb04395.x.

[32] Trumic E, Pranjić N, Begić L, Becić F. Prevalence of polypharmacy and drug interaction among hospitalized patients: opportunities and responsibilities in pharmaceutical care. Mater Sociomed. 2012;24(2):68–72. doi: 10.5455/msm.2012.24.68-72.

[33] Tamargo J, Rosano G, Walther T, Duarte J, Niessner A, Kaski JC, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):163–82. doi: 10.1093/ehjcvp/pwx042.

[34] Dormann H, Muth-Selbach U, Krebs S, Criegee-Rieck M, Tegeder I, Schneider HT, et al. Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf.
2000;22(2):161–8. doi: 10.2165/00002018-200022020-00007.

[35] Geer MI, Koul PA, Tanki SA, Shah MY. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital. J Pharmacol Toxicol Methods. 2016;81:323–34. doi: 10.1016/j.vascn.2016.04.011.

[36] Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA. 1991;266:2847–51. doi: 10.1136/qshc.2002.002972.

[37] Imbs JL, Pouyanne P, Haramburu F, Welsch M, Decker N, Blayac JP, et al. Iatrogénie médicamenteuse: estimation de sa prévalence dans les hôpitaux publics français. Centres régionaux de pharmacovigilance [iatrogenic medication: estimation of its prevalence in French public hospitals. Regional Centers of Pharmacovigilance]. Therapie. 1999;54(1):21–7 (In French).

[38] Somers A, Petrovic M, Robays H, Bogaert M. Reporting adverse drug reactions on a geriatric ward: a pilot project. Eur J Clin Pharmacol. 2003;58(10):707–14. doi: 10.1007/s00228-002-0535-5.38.

[39] Kaur S, Kapoor V, Mahajan R, Lal M, Gupta S. Monitoring of incidence, severity, and causality of adverse drug reactions in hospitalized patients with cardiovascular disease. Indian J Pharmacol. 2011;43(1):22–6. doi: 10.4103/0253-7613.75661.

[40] Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med. 1993;8:289–94. doi: 10.1007/BF02600138.

[41] Obradovic S, Djukanovic N, Todorovic Z, Markovic I, Zamaklar-Trifunovic D, Protic D, et al. Men with lower HDL cholesterol levels have significant increment of soluble CD40 ligand and high-sensitivity CRP levels following the cessation of long-term clopidogrel therapy. J Atheroscler Thromb. 2015;22(3):284–92. doi: 10.5551/jat.26765.

[42] Patel V, Lin FJ, Ojo O, Rao S, Yu S, Zhan L, et al. Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. Pharm Pract (Granada). 2014;12(3):438. doi: 10.4321/s1886-36552014000300007.